Omniscope Inc.

Based in the US, Omniscope empowers athletes through advanced technology for immune analysis and diagnostics, enhancing personalized healthcare solutions. Founded in 2021 and headquartered in Dover, US, Omniscope Inc. specializes in decoding the immune system. The company has conducted one deal as of January 7, 2025.

The founder's history is not publicly detailed, but the focus has been on innovating in the health monitoring space. Omniscope is a techbio company focused on decoding the immune system, offering products and services that revolve around the analysis and diagnostics of immune responses. Their primary offerings include the Omniscope Immune Portal, which allows users to track immune fitness and inflammation levels, and tools for generating cellular therapeutic designs through advanced immunosequencing techniques. The end use cases target health monitoring by enabling users to discover their immune age and disease protection, thus addressing the growing need for personalized healthcare solutions.

Omniscope collaborates with innovators in oncology, infectious diseases, and autoimmune diseases, serving a diverse client base that includes healthcare professionals, researchers, and patients. This technology is primarily marketed in North America and Europe, emphasizing its global applicability in enhancing healthcare outcomes. Omniscope generates revenue through a structured model that incorporates subscription services and partnerships. Clients may engage with the company's offerings through direct-to-consumer sales as well as B2B transactions with healthcare organizations and research institutions.

The transactions typically involve clients subscribing to the Omniscope Immune Portal to access personalized health insights and diagnostic capabilities. Specific details regarding pricing plans or flagship products have not been publicly disclosed; however, it is understood that the company’s innovative tools and services are designed to provide value in the burgeoning field of immunology and personalized medicine. This model positions Omniscope for sustainable revenue generation as they address the evolving healthcare landscape. In January 2025, Omniscope Inc.

raised an undisclosed amount of venture funding from new investor Barca Innovation Hub. The company plans to utilize this funding to develop new applications for monitoring health and optimizing athlete performance. Future initiatives include expanding their product offerings and entering new markets, although specific details on geographic targets and product release dates have not been disclosed.